 Altimmune NASDAQ: ALT shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune is a U.S.-based, clinical-stage immunotherapeutic biotechnology company. 